UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2016 UpToDate®

Immunity of the newborn

Authors
Ilan Dalal, MD
Chaim M Roifman, MD, FRCPC, FCACB
Section Editor
E Richard Stiehm, MD
Deputy Editor
Elizabeth TePas, MD, MS

INTRODUCTION

The fetal immune system develops in a sterile and protected environment and therefore lacks antigenic experience. It is also modulated in order to coexist with the mother's immune system. Soon after birth, the newborn is exposed to the "hostile world" of bacteria, viruses, fungi, and parasites and must immediately defend itself. The immunologic competence of the neonate progresses rapidly in the first three months of life as the cells involved in acquired immunity mature and gain antigenic experience. During this period, the neonate mainly depends upon components of the innate or antigen-independent immune system, including phagocytes, natural killer (NK) cells, antigen-presenting cells (APCs), humoral mediators of inflammation, and complement [1-3]. The breastfed infant also receives antimicrobial components in breast milk that help prevent certain acute infections. (See "Infant benefits of breastfeeding", section on 'Anti-microbial components' and "Infant benefits of breastfeeding", section on 'Prevention of illnesses while breastfeeding'.)

The overall performance of the immune system in the neonatal period is diminished in several important respects. As a result, very young infants are more susceptible than older infants to serious bacterial infection, as well as some viral and fungal infections.

Specifically, organisms that can cause significant morbidity in neonates include group B streptococci, Escherichia coli, herpes simplex virus (HSV), cytomegalovirus (CMV), varicella-zoster virus (VZV), respiratory syncytial virus (RSV), and Candida species [1]. These specific organisms cause neonatal infections more frequently than other organisms because the newborn has an increased risk of exposure to these pathogens, not because these organisms have special virulence determinants that are unique.

This review summarizes the knowledge about the function of the different arms of neonatal immunity, including what is known about neonatal defense against the pathogens mentioned above. More comprehensive reviews are available elsewhere [4-7]. Additional information about the development of the cellular components of the immune system is provided separately. (See "The development of immune cells in the fetus and neonate".)

Certain clinical scenarios, such as recurrent severe infections, chronic diarrhea, and failure to thrive, should prompt immediate evaluation for immunodeficiency states. The presentation of these disorders is presented in more detail separately. (See "Severe combined immunodeficiency (SCID): An overview" and "Recognition of immunodeficiency in the newborn period".)

                             

Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Nov 2016. | This topic last updated: Tue Jul 12 00:00:00 GMT+00:00 2016.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2016 UpToDate, Inc.
References
Top
  1. Maródi L. Neonatal innate immunity to infectious agents. Infect Immun 2006; 74:1999.
  2. PrabhuDas M, Adkins B, Gans H, et al. Challenges in infant immunity: implications for responses to infection and vaccines. Nat Immunol 2011; 12:189.
  3. Ygberg S, Nilsson A. The developing immune system - from foetus to toddler. Acta Paediatr 2012; 101:120.
  4. Lewis DB, Wenwei Tu. The physiologic immunodeficiency of immaturity. In: Immunologic disorders in infants and children, 5th ed, Stiehm ER, Ochs HD, Winkelstein JA (Eds), Elsevier Saunders, 2004. p.687.
  5. Adkins B, Leclerc C, Marshall-Clarke S. Neonatal adaptive immunity comes of age. Nat Rev Immunol 2004; 4:553.
  6. Lewis DB, Wilson CB. Developmental immunology and role of host defenses in fetal and neonatal susceptibility to infection. In: Infectious Diseases of the Fetus and Newborn, 7th ed., Klein JO, Maldonado Y, Nizet V, et al. (Eds), Elsevier Saunders, Philadelphia 2011. p.80.
  7. Dowling DJ, Levy O. Ontogeny of early life immunity. Trends Immunol 2014; 35:299.
  8. Correa-Rocha R, Pérez A, Lorente R, et al. Preterm neonates show marked leukopenia and lymphopenia that are associated with increased regulatory T-cell values and diminished IL-7. Pediatr Res 2012; 71:590.
  9. Altare F, Jouanguy E, Lamhamedi S, et al. Mendelian susceptibility to mycobacterial infection in man. Curr Opin Immunol 1998; 10:413.
  10. Roesler J, Kofink B, Wendisch J, et al. Listeria monocytogenes and recurrent mycobacterial infections in a child with complete interferon-gamma-receptor (IFNgammaR1) deficiency: mutational analysis and evaluation of therapeutic options. Exp Hematol 1999; 27:1368.
  11. Palin AC, Ramachandran V, Acharya S, Lewis DB. Human neonatal naive CD4+ T cells have enhanced activation-dependent signaling regulated by the microRNA miR-181a. J Immunol 2013; 190:2682.
  12. Shuai K, Schindler C, Prezioso VR, Darnell JE Jr. Activation of transcription by IFN-gamma: tyrosine phosphorylation of a 91-kD DNA binding protein. Science 1992; 258:1808.
  13. Shuai K, Stark GR, Kerr IM, Darnell JE Jr. A single phosphotyrosine residue of Stat91 required for gene activation by interferon-gamma. Science 1993; 261:1744.
  14. Lee HH, Hoeman CM, Hardaway JC, et al. Delayed maturation of an IL-12-producing dendritic cell subset explains the early Th2 bias in neonatal immunity. J Exp Med 2008; 205:2269.
  15. Marodi L. Down-regulation of Th1 responses in human neonates. Clin Exp Immunol 2002; 128:1.
  16. Wilson CB, Lewis DB. Basis and implications of selectively diminished cytokine production in neonatal susceptibility to infection. Rev Infect Dis 1990; 12 Suppl 4:S410.
  17. Gibson L, Piccinini G, Lilleri D, et al. Human cytomegalovirus proteins pp65 and immediate early protein 1 are common targets for CD8+ T cell responses in children with congenital or postnatal human cytomegalovirus infection. J Immunol 2004; 172:2256.
  18. Marchant A, Appay V, Van Der Sande M, et al. Mature CD8(+) T lymphocyte response to viral infection during fetal life. J Clin Invest 2003; 111:1747.
  19. Sandberg JK, Fast NM, Jordan KA, et al. HIV-specific CD8+ T cell function in children with vertically acquired HIV-1 infection is critically influenced by age and the state of the CD4+ T cell compartment. J Immunol 2003; 170:4403.
  20. Burchett SK, Corey L, Mohan KM, et al. Diminished interferon-gamma and lymphocyte proliferation in neonatal and postpartum primary herpes simplex virus infection. J Infect Dis 1992; 165:813.
  21. Chan T, Barra NG, Lee AJ, Ashkar AA. Innate and adaptive immunity against herpes simplex virus type 2 in the genital mucosa. J Reprod Immunol 2011; 88:210.
  22. Fernandez MA, Puttur FK, Wang YM, et al. T regulatory cells contribute to the attenuated primary CD8+ and CD4+ T cell responses to herpes simplex virus type 2 in neonatal mice. J Immunol 2008; 180:1556.
  23. Veiga-Parga T, Suryawanshi A, Mulik S, et al. On the role of regulatory T cells during viral-induced inflammatory lesions. J Immunol 2012; 189:5924.
  24. Hayward AR, Herberger M, Saunders D. Herpes simplex virus-stimulated gamma-interferon production by newborn mononuclear cells. Pediatr Res 1986; 20:398.
  25. Marchant A, Goldman M. T cell-mediated immune responses in human newborns: ready to learn? Clin Exp Immunol 2005; 141:10.
  26. FOWLER R Jr, SCHUBERT WK, WEST CD. Acquired partial tolerance to homologous skin grafts in the human infant at birth. Ann N Y Acad Sci 1960; 87:403.
  27. Rouleau M, Namikawa R, Antonenko S, et al. Antigen-specific cytotoxic T cells mediate human fetal pancreas allograft rejection in SCID-hu mice. J Immunol 1996; 157:5710.
  28. Orlandi F, Giambona A, Messana F, et al. Evidence of induced non-tolerance in HLA-identical twins with hemoglobinopathy after in utero fetal transplantation. Bone Marrow Transplant 1996; 18:637.
  29. Viëtor HE, Bolk J, Vreugdenhil GR, et al. Alterations in cord blood leukocyte subsets of patients with severe hemolytic disease after intrauterine transfusion therapy. J Pediatr 1997; 130:718.
  30. Ota MO, Vekemans J, Schlegel-Haueter SE, et al. Hepatitis B immunisation induces higher antibody and memory Th2 responses in new-borns than in adults. Vaccine 2004; 22:511.
  31. Vekemans J, Ota MO, Wang EC, et al. T cell responses to vaccines in infants: defective IFNgamma production after oral polio vaccination. Clin Exp Immunol 2002; 127:495.
  32. Hussey GD, Watkins ML, Goddard EA, et al. Neonatal mycobacterial specific cytotoxic T-lymphocyte and cytokine profiles in response to distinct BCG vaccination strategies. Immunology 2002; 105:314.
  33. Watkins ML, Semple PL, Abel B, et al. Exposure of cord blood to Mycobacterium bovis BCG induces an innate response but not a T-cell cytokine response. Clin Vaccine Immunol 2008; 15:1666.
  34. Ota MO, Vekemans J, Schlegel-Haueter SE, et al. Influence of Mycobacterium bovis bacillus Calmette-Guérin on antibody and cytokine responses to human neonatal vaccination. J Immunol 2002; 168:919.
  35. WARWICK WJ, GOOD RA, SMITH RT. Failure of passive transfer of delayed hypersensitivity in the newborn human infant. J Lab Clin Med 1960; 56:139.
  36. Kniker WT, Lesourd BM, McBryde JL, Corriel RN. Cell-mediated immunity assessed by Multitest CMI skin testing in infants and preschool children. Am J Dis Child 1985; 139:840.
  37. Stiehm ER, Fudenberg HH. Serum levels of immune globulins in health and disease: a survey. Pediatrics 1966; 37:715.
  38. Kobayashi RH, Hyman CJ, Stiehm ER. Immunologic maturation in an infant born to a mother with agammaglobulinemia. Am J Dis Child 1980; 134:942.
  39. Buckley RH. The immunologic system and disorders. In: Nelson's textbook of pediatrics, Behrman RE, Kliegman RM, Jenson HB (Eds), WB Saunders, Philadelphia 2004. p.681.
  40. Alford CA Jr, Stagno S, Reynolds DW. Diagnosis of chronic perinatal infections. Am J Dis Child 1975; 129:455.
  41. Kim D, Niewiesk S. Sidestepping maternal antibody: a lesson from measles virus vaccination. Expert Rev Clin Immunol 2011; 7:557.
  42. Bernbaum JC, Daft A, Anolik R, et al. Response of preterm infants to diphtheria-tetanus-pertussis immunizations. J Pediatr 1985; 107:184.
  43. Adenyi-Jones SC, Faden H, Ferdon MB, et al. Systemic and local immune responses to enhanced-potency inactivated poliovirus vaccine in premature and term infants. J Pediatr 1992; 120:686.
  44. Smolen P, Bland R, Heiligenstein E, et al. Antibody response to oral polio vaccine in premature infants. J Pediatr 1983; 103:917.
  45. Koblin BA, Townsend TR, Muñoz A, et al. Response of preterm infants to diphtheria-tetanus-pertussis vaccine. Pediatr Infect Dis J 1988; 7:704.
  46. Adderson EE, Shackelford PG, Quinn A, Carroll WL. Restricted Ig H chain V gene usage in the human antibody response to Haemophilus influenzae type b capsular polysaccharide. J Immunol 1991; 147:1667.
  47. Landers CD, Chelvarajan RL, Bondada S. The role of B cells and accessory cells in the neonatal response to TI-2 antigens. Immunol Res 2005; 31:25.
  48. Smith DH, Peter G, Ingram DL, et al. Responses of children immunized with the capsular polysaccharide of Hemophilus influenzae, type b. Pediatrics 1973; 52:637.
  49. Dalal I, Reid B, Nisbet-Brown E, Roifman CM. The outcome of patients with hypogammaglobulinemia in infancy and early childhood. J Pediatr 1998; 133:144.
  50. van den Biggelaar AH, Pomat WS. Immunization of newborns with bacterial conjugate vaccines. Vaccine 2013; 31:2525.
  51. Tosi MF. Innate immune responses to infection. J Allergy Clin Immunol 2005; 116:241.
  52. Belderbos M, Levy O, Bont L. Neonatal innate immunity in allergy development. Curr Opin Pediatr 2009; 21:762.
  53. Pettengill MA, van Haren SD, Levy O. Soluble mediators regulating immunity in early life. Front Immunol 2014; 5:457.
  54. Kai-Larsen Y, Gudmundsson GH, Agerberth B. A review of the innate immune defence of the human foetus and newborn, with the emphasis on antimicrobial peptides. Acta Paediatr 2014; 103:1000.
  55. Hofman FM, Danilovs JA, Taylor CR. HLA-DR (Ia)-positive dendritic-like cells in human fetal nonlymphoid tissues. Transplantation 1984; 37:590.
  56. Keever CA, Abu-Hajir M, Graf W, et al. Characterization of the alloreactivity and anti-leukemia reactivity of cord blood mononuclear cells. Bone Marrow Transplant 1995; 15:407.
  57. Harvey J, Jones DB, Wright DH. Differential expression of MHC- and macrophage-associated antigens in human fetal and postnatal small intestine. Immunology 1990; 69:409.
  58. Willems F, Vollstedt S, Suter M. Phenotype and function of neonatal DC. Eur J Immunol 2009; 39:26.
  59. Zaghouani H, Hoeman CM, Adkins B. Neonatal immunity: faulty T-helpers and the shortcomings of dendritic cells. Trends Immunol 2009; 30:585.
  60. Goriely S, Vincart B, Stordeur P, et al. Deficient IL-12(p35) gene expression by dendritic cells derived from neonatal monocytes. J Immunol 2001; 166:2141.
  61. De Wit D, Olislagers V, Goriely S, et al. Blood plasmacytoid dendritic cell responses to CpG oligodeoxynucleotides are impaired in human newborns. Blood 2004; 103:1030.
  62. Levy O, Zarember KA, Roy RM, et al. Selective impairment of TLR-mediated innate immunity in human newborns: neonatal blood plasma reduces monocyte TNF-alpha induction by bacterial lipopeptides, lipopolysaccharide, and imiquimod, but preserves the response to R-848. J Immunol 2004; 173:4627.
  63. Yan SR, Qing G, Byers DM, et al. Role of MyD88 in diminished tumor necrosis factor alpha production by newborn mononuclear cells in response to lipopolysaccharide. Infect Immun 2004; 72:1223.
  64. Maródi L, Káposzta R, Nemes E. Survival of group B streptococcus type III in mononuclear phagocytes: differential regulation of bacterial killing in cord macrophages by human recombinant gamma interferon and granulocyte-macrophage colony-stimulating factor. Infect Immun 2000; 68:2167.
  65. Bektas S, Goetze B, Speer CP. Decreased adherence, chemotaxis and phagocytic activities of neutrophils from preterm neonates. Acta Paediatr Scand 1990; 79:1031.
  66. Ezekowitz RA, Sastry K, Bailly P, Warner A. Molecular characterization of the human macrophage mannose receptor: demonstration of multiple carbohydrate recognition-like domains and phagocytosis of yeasts in Cos-1 cells. J Exp Med 1990; 172:1785.
  67. Maródi L, Korchak HM, Johnston RB Jr. Mechanisms of host defense against Candida species. I. Phagocytosis by monocytes and monocyte-derived macrophages. J Immunol 1991; 146:2783.
  68. D'Ambola JB, Sherman MP, Tashkin DP, Gong H Jr. Human and rabbit newborn lung macrophages have reduced anti-Candida activity. Pediatr Res 1988; 24:285.
  69. Tosi M. Normal and impaired immunologic responses to infection. In: Feigin and Cherry’s Textbook of Pediatric Infectious Diseases, 7th ed, Cherry JD, Demmler-Harrison GJ, Kaplan SL, Steinbach WJ, Hotez P (Eds), Saunders, Philadelphia 2014. p.22.
  70. Carr R. Neutrophil production and function in newborn infants. Br J Haematol 2000; 110:18.
  71. Molloy EJ, O'Neill AJ, Grantham JJ, et al. Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor have differential effects on neonatal and adult neutrophil survival and function. Pediatr Res 2005; 57:806.
  72. Miura E, Procianoy RS, Bittar C, et al. A randomized, double-masked, placebo-controlled trial of recombinant granulocyte colony-stimulating factor administration to preterm infants with the clinical diagnosis of early-onset sepsis. Pediatrics 2001; 107:30.
  73. Teng P, Cao Y, Wang WX, et al. [The shh promoter of zebrafish directs the expression of GFP in notochord]. Yi Chuan Xue Bao 2004; 31:39.
  74. Koenig JM, Simon J, Anderson DC, et al. Diminished soluble and total cellular L-selectin in cord blood is associated with its impaired shedding from activated neutrophils. Pediatr Res 1996; 39:616.
  75. Lorant DE, Li W, Tabatabaei N, et al. P-selectin expression by endothelial cells is decreased in neonatal rats and human premature infants. Blood 1999; 94:600.
  76. Tcharmtchi MH, Smith CW, Mariscalco MM. Neonatal neutrophil interaction with P-selectin: contribution of P-selectin glycoprotein ligand-1 and sialic acid. J Leukoc Biol 2000; 67:73.
  77. Merry C, Puri P, Reen DJ. Defective neutrophil actin polymerisation and chemotaxis in stressed newborns. J Pediatr Surg 1996; 31:481.
  78. Falconer AE, Carr R, Edwards SW. Impaired neutrophil phagocytosis in preterm neonates: lack of correlation with expression of immunoglobulin or complement receptors. Biol Neonate 1995; 68:264.
  79. Fujiwara T, Kobayashi T, Takaya J, et al. Plasma effects on phagocytic activity and hydrogen peroxide production by polymorphonuclear leukocytes in neonates. Clin Immunol Immunopathol 1997; 85:67.
  80. Stroobant J, Harris MC, Cody CS, et al. Diminished bactericidal capacity for group B Streptococcus in neutrophils from "stressed" and healthy neonates. Pediatr Res 1984; 18:634.
  81. Levy O, Martin S, Eichenwald E, et al. Impaired innate immunity in the newborn: newborn neutrophils are deficient in bactericidal/permeability-increasing protein. Pediatrics 1999; 104:1327.
  82. Ueno Y, Koizumi S, Yamagami M, et al. Characterization of hemopoietic stem cells (CFUc) in cord blood. Exp Hematol 1981; 9:716.
  83. Becker ID, Robinson OM, Bazán TS, et al. Bactericidal capacity of newborn phagocytes against group B beta-hemolytic streptococci. Infect Immun 1981; 34:535.
  84. Conly ME, Speert DP. Human neonatal monocyte-derived macrophages and neutrophils exhibit normal nonopsonic and opsonic receptor-mediated phagocytosis and superoxide anion production. Biol Neonate 1991; 60:361.
  85. Joyner JL, Augustine NH, Taylor KA, et al. Effects of group B streptococci on cord and adult mononuclear cell interleukin-12 and interferon-gamma mRNA accumulation and protein secretion. J Infect Dis 2000; 182:974.
  86. Azizia M, Lloyd J, Allen M, et al. Immune status in very preterm neonates. Pediatrics 2012; 129:e967.
  87. Bessler H, Mendel C, Straussberg R, et al. Effects of dexamethasone on IL-1beta, IL-6, and TNF-alpha production by mononuclear cells of newborns and adults. Biol Neonate 1999; 75:225.
  88. Kollmann TR, Levy O, Montgomery RR, Goriely S. Innate immune function by Toll-like receptors: distinct responses in newborns and the elderly. Immunity 2012; 37:771.
  89. Yu HR, Chang JC, Chen RF, et al. Different antigens trigger different Th1/Th2 reactions in neonatal mononuclear cells (MNCs) relating to T-bet/GATA-3 expression. J Leukoc Biol 2003; 74:952.
  90. Brunell PA. Fetal and neonatal varicella-zoster infections. Semin Perinatol 1983; 7:47.
  91. Parrott RH, Kim HW, Arrobio JO, et al. Epidemiology of respiratory syncytial virus infection in Washington, D.C. II. Infection and disease with respect to age, immunologic status, race and sex. Am J Epidemiol 1973; 98:289.
  92. Krishnan S, Craven M, Welliver RC, et al. Differences in participation of innate and adaptive immunity to respiratory syncytial virus in adults and neonates. J Infect Dis 2003; 188:433.
  93. Klein RB, Fischer TJ, Gard SE, et al. Decreased mononuclear and polymorphonuclear chemotaxis in human newborns, infants, and young children. Pediatrics 1977; 60:467.
  94. Kurt-Jones EA, Belko J, Yu C, et al. The role of toll-like receptors in herpes simplex infection in neonates. J Infect Dis 2005; 191:746.
  95. Schultz C, Rott C, Temming P, et al. Enhanced interleukin-6 and interleukin-8 synthesis in term and preterm infants. Pediatr Res 2002; 51:317.
  96. Shearer WT, Rosenblatt HM, Gelman RS, et al. Lymphocyte subsets in healthy children from birth through 18 years of age: the Pediatric AIDS Clinical Trials Group P1009 study. J Allergy Clin Immunol 2003; 112:973.
  97. Phillips JH, Hori T, Nagler A, et al. Ontogeny of human natural killer (NK) cells: fetal NK cells mediate cytolytic function and express cytoplasmic CD3 epsilon,delta proteins. J Exp Med 1992; 175:1055.
  98. Baley JE, Schacter BZ. Mechanisms of diminished natural killer cell activity in pregnant women and neonates. J Immunol 1985; 134:3042.
  99. Nair MP, Schwartz SA, Menon M. Association of decreased natural and antibody-dependent cellular cytotoxicity and production of natural killer cytotoxic factor and interferon in neonates. Cell Immunol 1985; 94:159.
  100. Merrill JD, Sigaroudinia M, Kohl S. Characterization of natural killer and antibody-dependent cellular cytotoxicity of preterm infants against human immunodeficiency virus-infected cells. Pediatr Res 1996; 40:498.
  101. Kohl S. Human neonatal natural killer cell cytotoxicity function. Pediatr Infect Dis J 1999; 18:635.
  102. Johnston RB Jr, Altenburger KM, Atkinson AW Jr, Curry RH. Complement in the newborn infant. Pediatrics 1979; 64:781.
  103. Davis CA, Vallota EH, Forristal J. Serum complement levels in infancy: age related changes. Pediatr Res 1979; 13:1043.
  104. McGreal EP, Hearne K, Spiller OB. Off to a slow start: under-development of the complement system in term newborns is more substantial following premature birth. Immunobiology 2012; 217:176.
  105. Tasker L, Marshall-Clarke S. Functional responses of human neonatal B lymphocytes to antigen receptor cross-linking and CpG DNA. Clin Exp Immunol 2003; 134:409.
  106. Wolach B, Dolfin T, Regev R, et al. The development of the complement system after 28 weeks' gestation. Acta Paediatr 1997; 86:523.
  107. Lassiter HA, Watson SW, Seifring ML, Tanner JE. Complement factor 9 deficiency in serum of human neonates. J Infect Dis 1992; 166:53.
  108. Drossou V, Kanakoudi F, Diamanti E, et al. Concentrations of main serum opsonins in early infancy. Arch Dis Child Fetal Neonatal Ed 1995; 72:F172.
  109. Forman ML, Stiehm ER. Impaired opsonic activity but normal phagocytosis in low-birth-weight infants. N Engl J Med 1969; 281:926.
  110. Oudshoorn AM, van den Dungen FA, Bach KP, et al. Mannose-binding lectin in term newborns and their mothers: genotypic and phenotypic relationship. Hum Immunol 2008; 69:344.
  111. Barnard DR, Arthur MM. Fibronectin (cold insoluble globulin) in the neonate. J Pediatr 1983; 102:453.
  112. Haskó G, Cronstein BN. Adenosine: an endogenous regulator of innate immunity. Trends Immunol 2004; 25:33.
  113. Pettengill M, Robson S, Tresenriter M, et al. Soluble ecto-5'-nucleotidase (5'-NT), alkaline phosphatase, and adenosine deaminase (ADA1) activities in neonatal blood favor elevated extracellular adenosine. J Biol Chem 2013; 288:27315.
  114. Levy O. A Pediatric Perspective on Antimicrobial Proteins and Peptides: Expression, Function, and Clinical Relevance. In: Antimicrobial Peptides in Human Health and Disease, Gallo RL (Ed), Horizon Bioscience, Norfolk, UK 2005. p.305.
  115. Strunk T, Doherty D, Richmond P, et al. Reduced levels of antimicrobial proteins and peptides in human cord blood plasma. Arch Dis Child Fetal Neonatal Ed 2009; 94:F230.